BioCardia (STU:6JU0) FFO


STU:6JU0 BioCardia Inc STU:6JU0
17 GF Score
Price €0.27
GF Value €0.01
! 1 Warning Sign
View Full Analysis

What is BioCardia FFO?

FFO (Funds from operations) only applies to REITs.

STU:6JU0
17GF Score
BioCardia Inc STU:6JU0
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioCardia (STU:6JU0) Overvalued in 2026?

Based on GuruFocus' analysis, BioCardia stock appears to be overvalued. The current stock price of €0.27 is trading 2600% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6JU0:

  • FFO:
  • GF Value™: €0.01 vs. price of €0.27 (2600% above fair value)
  • GF Score™: 17/100 with 1 warning sign

No single metric tells the full story. See the STU:6JU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
17GF Score

Get the complete analysis for STU:6JU0

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.01
GF Value